Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04682509
Other study ID # 20-01386
Secondary ID
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date March 20, 2022
Est. completion date March 14, 2024

Study information

Verified date February 2024
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV.


Description:

This is a prospective, open-label, single-center, pilot study. The patient population will include 20 patients who are on the kidney transplant waitlist at NYU Langone Health, are hepatitis C virus (HCV) negative, are willing to accept an organ from an HCV positive donor, and consent to participate in this trial. Study subjects will receive a kidney transplant from a deceased donor who tested positive for HCV as confirmed by nucleic acid amplification testing (NAT) per standard of care. All study subjects will receive a two week course of preemptive therapy with glecaprevir/pibrentasvir (Mavyret®), starting on postoperative day (POD) 0 prior to the transplant. If HCV RNA is undetectable after 2 weeks of therapy, Mavyret will be discontinued and study subjects will be followed with an intensive HCV monitoring protocol. If HCV RNA is detectable after 2 weeks of therapy, Mavyret will be continued to complete a full course of 8 weeks per standard of care. All patients will undergo close monitoring and surveillance for HCV viremia post-transplant to ensure that sustained virologic response (SVR) is achieved.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date March 14, 2024
Est. primary completion date May 16, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - At least 18 years of age - Listed for kidney transplantation at NYU Langone Health and willing to accept HCV positive donor organs - Able to complete routine post-transplant visits and study visits for a minimum of 1 year after transplantation - Women of childbearing potential must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Stategy (REMS) after transplant due to increased risk of birth defects and/or miscarriage - Both men and women must agree to use at least one barrier method of contraception after transplant to prevent any secretion exchange - Able and willing to provide informed consent - Receive an organ offer for a kidney from a deceased donor that: - Is HCV NAT positive - Meets all standard criteria for organ acceptability at NYU Langone Transplant Institute Exclusion Criteria: - HCV RNA positive or history of previously treated HCV - Evidence of active hepatitis B infection or on active antiviral treatment of HBV - HIV positivity - Pregnant or nursing (lactacting) women - Current use of atazanavir or rifampin - Known hypersensitivity to glecaprevir and/or pibrentasvir - Current or history of decompensated liver disease - Recipients of dual organs (i.e. simultaneous liver and kidney transplant, simultaneous kidney and pancreas transplant, or simultaneous heart and kidney transplant) - Receive an organ offer for a kidney from a deceased donor that is: - Confirmed HIV positive - Confirmed HBV positive (positive hepatitis B surface antigen, and/or detectable hepatitis B virus DNA) - Known to have previously failed DAA therapy for treatment for HCV - HCV antibody positive, but NAT negative

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glecaprevir/pibrentasvir
Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).

Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Percentage of Incidence of sustained clearance of HCV (cure) 12 weeks after treatment of viremia Measured in percentage of patients with SVR after treatment for HCV after kidney transplant. SVR will be defined as the absence of detectable HCV RNA Quantitative (PCR) testing 12 weeks after the completion of the treatment course. Visit 2 (Day 1) , Visit 3 (Day 3) , Visit 4 (Day 7), Visit 5 (Day 13), Visit 16 (Day 365)
Secondary Percentage of Overall patient and graft survival at 1 year post-transplant Patients will have regular follow-up as standard-of-care for all kidney transplant recipients. Patients' survival will be readily apparent. Furthermore, all deaths of transplant recipients and allograft losses within the first year of transplant are required to be reported to UNOS. Survival rates will be reported as a percentage. Visit 1 (Day 0), Visit 16 (Day 365)
Secondary Change in the Allograft function This parameter is being used to measure overall graft function and will be described using the median value at 1 year post transplant for the cohort. All transplant recipients will have regular follow-up as standard-of-care and eGFR will be calculated using the MDRD equation. Visit 1 (Day 0), Visit 16 (Day 365)
Secondary Percentage of Incidence and grade of biopsy-proven rejection All transplant recipients will have regular follow-up as routine clinical care and as such, will receive for cause biopsies per standard of care if there is a clinical suspicion of rejection. Biopsies will be read by a renal pathologist per standard of care and reported in the EPIC system. The incidence of rejection will be calculated as a percentage of the patients with diagnosed rejection on biopsy within 1 year of transplant. Visit 1 (Day 0), Visit 16 (Day 365)
Secondary Time course to transplantation (median) Time to transplantation will be measured from the time of listing (recorded in EPIC) to time of transplant and also time from written acknowledgment of willingness to participate in the trial to time of transplant. Screening vist, Visit 1 (Day 0)
Secondary Percentage of Incidence HCV viremia post-transplant and after 2 weeks of treatment Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study. A patient will be considered to be viremic when a post-transplant HCV RNA Quantitative (PCR) test is positive. The incidence of viremia after transplant will be calculated as the percent of the patients transplanted with an HCV-positive donor who subsequently developed HCV viremia (detected by RNA Quantitative (PCR) testing). The incidence of viremia after two weeks of treatment will be calculated as the percentage of the patients with detectable HCV viremia (detected by RNA Quantitative (PCR) testing) after completing 2 weeks of treatment with glecaprevir/pibrentasvir and therefore require continuation of therapy to complete an 8 week course Visit 1 (Day 0), Visit 5 (Day 13), Visit 16 (Day 365)
Secondary Time course of exposure to development of clinically detectable viremia in those who develop viremia Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study to find the median time to viremia with standard deviations. If the HCV RNA Quantitative (PCR) test is positive at any time point, we will calculate the time from transplant to detectable HCV RNA Quantitative (PCR). Visit 1 (Day 0) to Visit 16 (Days 364)
Secondary Time course of clearance of viremia after treatment initiation Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study to find the median time to clearance with standard deviations. If the HCV RNA Quantitative (PCR) test is positive at any time point, we will calculate the time to documented clearance as indicated by an undetectable HCV RNA Quantitative (PCR), Visit 1 (Day 0) to Visit 16 (Days 364)
Secondary Percentage of Incidence of treatment failure/treatment resistant strains of HCV If SVR12 is not achieved with either a 2 week or 8 week course of glecaprevir/pibrentasvir, it will be considered a treatment failure and resistance testing will be performed. The incidence will be reported as a percentage. Visit 1 (Day 0), Visit 5 (Day 13), Visit 9 (Day 56)
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Completed NCT03456648 - Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study Phase 2
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT01252771 - Phosphate Kinetic Modeling 2 Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00294502 - Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Phase 4
Completed NCT05011136 - Physician Reimbursement Home Patients
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Completed NCT02278562 - Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 Phase 2
Completed NCT01424787 - Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering) N/A
Terminated NCT00580762 - Bariatric Surgery for ESRD Patients vs Control N/A
Recruiting NCT05339139 - SAfety of Regional Citrate Anticoagulation (SARCA Study) Phase 3
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT05309785 - Safety and Efficacy of Canagliflozin in Advanced CKD Phase 4
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Not yet recruiting NCT02596386 - Examination of Potassium Levels in Saliva in ESRD Patients N/A
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Active, not recruiting NCT02270515 - Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease N/A
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A